{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T15:00:56Z","timestamp":1794668456897,"version":"4.9.1"},"reference-count":62,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","gastrojournal.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1053\/j.gastro.2024.04.029","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T15:19:32Z","timestamp":1714403972000},"page":"689-703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":129,"title":["Association of GLP-1 Receptor Agonists and Hepatocellular Carcinoma Incidence and Hepatic Decompensation in Patients With Type 2 Diabetes"],"prefix":"10.1053","volume":"167","author":[{"given":"Lindsey","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan A.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Kaelber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2024.04.029_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3322\/caac.21440","article-title":"Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States","volume":"68","author":"Islami","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2024.04.029_bib5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2024.04.029_bib6","author":"Schwartz","year":"2024"},{"key":"10.1053\/j.gastro.2024.04.029_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1053\/j.gastro.2024.04.029_bib8","doi-asserted-by":"crossref","first-page":"e170671","DOI":"10.1172\/jci.insight.170671","article-title":"The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission","volume":"8","author":"Chuong","year":"2023","journal-title":"JCI Insight"},{"key":"10.1053\/j.gastro.2024.04.029_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101865","article-title":"Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial","volume":"57","author":"Lengsfeld","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1053\/j.gastro.2024.04.029_bib10","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in\u00a0vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"Gupta","year":"2010","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2024.04.029_bib11","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S2468-1253(21)00261-2","article-title":"Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review","volume":"7","author":"Mantovani","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.04.029_bib12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S2468-1253(22)00338-7","article-title":"Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease","volume":"8","author":"Targher","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.04.029_bib13","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A\u00a0placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.04.029_bib14","article-title":"TriNetX - The World\u2019s Largest, Living Ecosystem of Real-World Data and Evidence","year":"2021","journal-title":"TriNetX"},{"key":"10.1053\/j.gastro.2024.04.029_bib15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/wps.20921","article-title":"Increased risk for COVID-19 breakthrough infection in fully vaccinated patients with substance use disorders in the United States between December 2020 and August 2021","volume":"21","author":"Wang","year":"2022","journal-title":"World Psychiatry"},{"key":"10.1053\/j.gastro.2024.04.029_bib16","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jamapediatrics.2022.0945","article-title":"Incidence rates and clinical outcomes of SARS-CoV-2 infection with the omicron and delta variants in children younger than 5 years in the US","volume":"178","author":"Wang","year":"2022","journal-title":"JAMA Pediatr"},{"key":"10.1053\/j.gastro.2024.04.029_bib17","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1001\/jama.2022.0210","article-title":"Comparison of mRNA-1273 and BNT162b2 vaccines on breakthrough SARS-CoV-2 infections, hospitalizations, and death during the delta-predominant period","volume":"327","author":"Wang","year":"2022","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2024.04.029_bib18","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/alz.12669","article-title":"COVID-19 breakthrough infections and hospitalizations among vaccinated patients with dementia in the United States between December 2020 and August 2021","volume":"19","author":"Wang","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1053\/j.gastro.2024.04.029_bib19","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1001\/jamaoncol.2022.1096","article-title":"Breakthrough SARS-CoV-2 infections, hospitalizations, and mortality in vaccinated patients with cancer in the US between December 2020 and November 2021","volume":"8","author":"Wang","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.gastro.2024.04.029_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100931","article-title":"COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: a clarion call for maintaining mitigation and ramping-up research","volume":"54","author":"Wang","year":"2022","journal-title":"Blood Rev"},{"key":"10.1053\/j.gastro.2024.04.029_bib21","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.37575","article-title":"Risks of SARS-CoV-2 breakthrough infection and hospitalization in fully vaccinated patients with multiple myeloma","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1053\/j.gastro.2024.04.029_bib22","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41380-022-01903-1","article-title":"Association of COVID-19 with endocarditis in patients with cocaine or opioid use disorders in the US","volume":"28","author":"Wang","year":"2023","journal-title":"Mol Psychiatry"},{"key":"10.1053\/j.gastro.2024.04.029_bib23","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1111\/add.16168","article-title":"Repurposing ketamine to treat cocaine use disorder: integration of artificial intelligence-based prediction, expert evaluation, clinical corroboration and mechanism of action analyses","volume":"118","author":"Gao","year":"2023","journal-title":"Addiction"},{"key":"10.1053\/j.gastro.2024.04.029_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.55496","article-title":"Association of recent SARS-CoV-2 infection with new-onset\u00a0alcohol use disorder, January 2020 through January 2022","volume":"6","author":"Olaker","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1053\/j.gastro.2024.04.029_bib25","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/jclp.23582","article-title":"Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder","volume":"79","author":"Wang","year":"2023","journal-title":"J\u00a0Clin Psychol"},{"key":"10.1053\/j.gastro.2024.04.029_bib26","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.3390\/cancers14194948","article-title":"Time trend and association of early-onset colorectal cancer with diverticular disease in the United States: 2010\u20132021","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers"},{"key":"10.1053\/j.gastro.2024.04.029_bib27","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/jamaoncol.2023.5573","article-title":"GLP-1 receptor agonists and colorectal cancer risk in drug-naive patients with type 2 diabetes, with and without overweight\/obesity","volume":"10","author":"Wang","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.gastro.2024.04.029_bib28","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"10.1053\/j.gastro.2024.04.029_bib29","first-page":"1","article-title":"Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study.","author":"Wang","year":"2024","journal-title":"Mol Psychiatry"},{"key":"10.1053\/j.gastro.2024.04.029_bib31","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/pds.2148","article-title":"Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study","volume":"20","author":"Lo","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1053\/j.gastro.2024.04.029_bib32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nrc3215","article-title":"The insulin and insulin-like growth factor receptor family in neoplasia: an update","volume":"12","author":"Pollak","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.gastro.2024.04.029_bib33","article-title":"Non-alcoholic fatty liver disease and diabetes mellitus as growing aetiologies of hepatocellular carcinoma","volume":"5","author":"Talamantes","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1053\/j.gastro.2024.04.029_bib34","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/ajg.2013.5","article-title":"Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis","volume":"108","author":"Singh","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.04.029_bib35","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cgh.2008.02.012","article-title":"Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients","volume":"6","author":"Ohki","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.04.029_bib36","article-title":"Could new weight-loss drugs like ozempic treat addiction?","author":"Reardon","year":"2023","journal-title":"Scientific American"},{"key":"10.1053\/j.gastro.2024.04.029_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2023.102849","article-title":"Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: a systematic review and meta-analysis","volume":"17","author":"Bandyopadhyay","year":"2023","journal-title":"Diabetes Metab Syndr"},{"key":"10.1053\/j.gastro.2024.04.029_bib38","article-title":"Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus","volume":"10","author":"Hemmingsen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.gastro.2024.04.029_bib39","doi-asserted-by":"crossref","first-page":"8532","DOI":"10.1038\/s41598-019-44447-1","article-title":"Incident hepatocellular carcinoma risk in patients treated with a sulfonylurea: a nationwide, nested, case-control study","volume":"9","author":"Lee","year":"2019","journal-title":"Sci Rep"},{"key":"10.1053\/j.gastro.2024.04.029_bib40","doi-asserted-by":"crossref","first-page":"E1170","DOI":"10.1210\/jc.2012-1162","article-title":"Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus","volume":"97","author":"Chang","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1053\/j.gastro.2024.04.029_bib41","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.3748\/wjg.v19.i15.2298","article-title":"Dipeptidyl peptidase-4: a key player in chronic liver disease","volume":"19","author":"Itou","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.04.029_bib42","doi-asserted-by":"crossref","first-page":"574","DOI":"10.14218\/JCTH.2022.00278","article-title":"SGLT-2 inhibitor and GLP-1 receptor agonist treatment for patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: Is their combination the optimal treatment option?","volume":"10","author":"Patoulias","year":"2022","journal-title":"J\u00a0Clin Transl Hepatol"},{"key":"10.1053\/j.gastro.2024.04.029_bib43","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.dld.2020.08.021","article-title":"Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map","volume":"53","author":"Kumar","year":"2021","journal-title":"Dig Liver Dis"},{"key":"10.1053\/j.gastro.2024.04.029_bib44","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body fatness and cancer\u2014viewpoint of the IARC Working Group","volume":"375","author":"Lauby-Secretan","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.04.029_bib45","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s12325-021-01710-0","article-title":"Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists","volume":"38","author":"Ard","year":"2021","journal-title":"Adv Ther"},{"key":"10.1053\/j.gastro.2024.04.029_bib46","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/aje\/155.4.323","article-title":"Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women","volume":"155","author":"Donato","year":"2002","journal-title":"Am J Epidemiol"},{"key":"10.1053\/j.gastro.2024.04.029_bib47","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1053\/jhep.2002.36780","article-title":"Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus","volume":"36","author":"Hassan","year":"2002","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2024.04.029_bib48","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1093\/jnci\/djr395","article-title":"Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study","volume":"103","author":"Trichopoulos","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1053\/j.gastro.2024.04.029_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104642","article-title":"Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats","volume":"93","author":"Aran\u00e4s","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1053\/j.gastro.2024.04.029_bib50","doi-asserted-by":"crossref","first-page":"e159863","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"key":"10.1053\/j.gastro.2024.04.029_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-072707","article-title":"Exenatide as an adjunct to nicotine patch for smoking cessation and prevention of postcessation weight gain among treatment-seeking smokers with pre-diabetes and\/or overweight: study protocol for a randomised, placebo-controlled clinical trial","volume":"13","author":"Yammine","year":"2023","journal-title":"BMJ Open"},{"key":"10.1053\/j.gastro.2024.04.029_bib52","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon-like peptide 1 (GLP-1) in addictive disorders","volume":"179","author":"Klausen","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1053\/j.gastro.2024.04.029_bib53","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review","volume":"32","author":"Chan","year":"2023","journal-title":"J\u00a0Obes Metab Syndr"},{"key":"10.1053\/j.gastro.2024.04.029_bib54","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.23527","article-title":"The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis","volume":"51","author":"Ascha","year":"2010","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2024.04.029_bib55","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease","volume":"155","author":"Kanwal","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.04.029_bib56","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.04.029_bib57","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.04.029_bib58","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2024.04.029_bib59","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2337\/dc10-2229","article-title":"Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study","volume":"34","author":"Williamson","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2024.04.029_bib60","doi-asserted-by":"crossref","first-page":"610","DOI":"10.7150\/ijbs.29599","article-title":"Obesity, nonalcoholic fatty liver disease and adipocytokines network in promotion of cancer","volume":"15","author":"Divella","year":"2019","journal-title":"Int J Biol Sci"},{"key":"10.1053\/j.gastro.2024.04.029_bib61","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12916-018-1103-x","article-title":"Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease","volume":"16","author":"Alexander","year":"2018","journal-title":"BMC Med"},{"key":"10.1053\/j.gastro.2024.04.029_bib62","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41590-018-0044-z","article-title":"The immunology of hepatocellular carcinoma","volume":"19","author":"Ringelhan","year":"2018","journal-title":"Nat Immunol"},{"key":"10.1053\/j.gastro.2024.04.029_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent","volume":"14","author":"Mehdi","year":"2023","journal-title":"Front Immunol"},{"key":"10.1053\/j.gastro.2024.04.029_bib64","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/apt.15316","article-title":"Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and\/or\u00a0obesity","volume":"50","author":"Newsome","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.04.029_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.997578","article-title":"GLP-1 receptor agonist as a modulator of innate immunity","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"10.1053\/j.gastro.2024.04.029_bib66","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bbrc.2018.12.149","article-title":"Liraglutide protects against inflammatory stress in non-alcoholic fatty liver by modulating Kupffer cells M2 polarization via cAMP-PKA-STAT3 signaling pathway","volume":"510","author":"Li","year":"2019","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508524004943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508524004943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T05:33:37Z","timestamp":1731562417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508524004943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0016508524004943"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2024.04.029","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of GLP-1 Receptor Agonists and Hepatocellular Carcinoma Incidence and Hepatic Decompensation in Patients With Type 2 Diabetes","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2024.04.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}